- Docetaxel-Cisplatin-5-FU Combination Chemotherapy as a First-line Treatment in Patients with Metastatic or Recurred Gastric Cancer
-
Kim JH, Lee YC
- KMID: 782915
- Korean J Gastroenterol.
- 2007 Sep;50(3):207-209.
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Nail Changes During Docetaxel Containing Combination Chemotherapy
-
Woo IS, Shim KH, Kim GY, Lee MA, Kang JH, Hong YS, Lee KS
- KMID: 759702
- Korean J Intern Med.
- 2004 Jun;19(2):132-133.
Nail toxicity following systemic chemotherapy is common. Onychopathy during the period of neutropenia following chemotherapy may cause subungual abscesses and serious infection. Despite taxoid-related toxicity being increasingly reported since 2000,... -
- CITED
-
- Close
- SHARE
-
- Close
- Weekly Low-Dose Docetaxel for Salvage Chemotherapy in Pretreated Elderly or Poor Performance Status Patients with Non-small Cell Lung Cancer
-
Lee KW, Lim JH, Kim JH, Lee CT, Lee JS
- KMID: 1107523
- J Korean Med Sci.
- 2008 Dec;23(6):992-998.
- doi: 10.3346/jkms.2008.23.6.992
Although docetaxel monotherapy has shown clinical benefits for previously treated patients with advanced non-small cell lung cancer (NSCLC), the efficacy of salvage docetaxel chemotherapy for elderly patients or patients with... -
- CITED
-
- Close
- SHARE
-
- Close
- Docetaxel-Cisplatin-5-FU Combination Chemotherapy as a First-line Treatment in Patients with Metastatic or Recurred Gastric Cancer
-
Kang SH, Kim JI, Goh PG, Hwang SW, Kwon DS, Nam KW, Kang HM, Kang YS, Moon HS, Kim SH, Seong JK, Lee BS, Jeong HY
- KMID: 782906
- Korean J Gastroenterol.
- 2007 Sep;50(3):157-163.
BACKGROUND/AIMS: The purpose of this study was to investigate the efficacy and safety of 'docetaxel-5-FU-cisplatin' combination chemotherapy as a first-line treatment in patients with metastatic or recurrent gastric cancer. ... -
- CITED
-
- Close
- SHARE
-
- Close
- Docetaxel Monotherapy as Second-Line Treatment for Pretreated Advanced Non-Small Cell Lung Cancer Patients
-
Ko YH, Lee MA, Hong YS, Lee KS, Park HJ, Yoo IR, Kim YS, Kim YK, Jo KH, Wang YP, Lee KY, Kang JH
- KMID: 1785624
- Korean J Intern Med.
- 2007 Sep;22(3):178-185.
- doi: 10.3904/kjim.2007.22.3.178
BACKGROUND: Second-line chemotherapy offers advanced non-small cell lung cancer (NSCLC) patients a small, but significant increase in survival. Docetaxel is usually administered as a 3-week schedule, yet there is... -
- CITED
-
- Close
- SHARE
-
- Close
